Addyi (Flibanserin) Interaction Profile: Alcohol, Drugs, and Vaccines Explained

What Is Addyi and Who Is It For?

Flibanserin, sold as Addyi, is a non-hormonal, centrally acting drug approved by the FDA in August 2015 for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It acts primarily as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist, with additional dopamine D4 agonist activity. That combination of receptor actions is thought to shift the balance of excitatory and inhibitory neurotransmitters in circuits governing sexual motivation.

HSDD affects an estimated 10 percent of U.S. Women, making it the most common female sexual dysfunction. Yet the evidence base, particularly in women over 45, remains thinner than most clinicians would like.

What "Premenopausal" Actually Means Here

The FDA approval is specifically limited to premenopausal women. The key trials, the VIOLET, BEGONIA, and SNOWDROP studies, enrolled women with natural menstrual cycles and a mean age of approximately 36 years. Women in perimenopause or postmenopause were not included in the registration trials, so prescribing Addyi to a woman who has already entered perimenopause is technically off-label. Some clinicians do prescribe it in early perimenopause when cycles are still irregular but present; if you are in that stage, discuss the evidence gap explicitly with your provider.

The VIOLET Trial Numbers Worth Knowing

The VIOLET trial showed that women taking flibanserin 100 mg at bedtime experienced 0.5 to 1.0 more satisfying sexual events per month compared with placebo over 24 weeks. That number sounds modest, and it is. The drug is not a cure. It shifts desire frequency at a population level; individual responses vary considerably, and the FDA required a Risk Evaluation and Mitigation Strategy (REMS) program, called ADDYI REMS, precisely because the benefit-risk ratio is narrow.

The Boxed Warning: Alcohol Is the Most Dangerous Interaction

The single most clinically significant interaction for flibanserin is alcohol. The FDA added a boxed warning after a dedicated alcohol interaction study showed profound additive CNS and cardiovascular depression.

What Happens When You Mix the Two

When women consumed alcohol at the same time as or within two hours of a bedtime flibanserin dose, blood pressure dropped to levels consistent with clinical hypotension, and some participants experienced syncope (fainting). The approved label states that alcohol must be avoided for at least two hours before and through the night after taking the dose. Practically, this means if you take Addyi at 10 p.m., you should not drink after approximately 8 p.m. On days you take the drug.

The mechanism is additive CNS depression combined with flibanserin's mild alpha-adrenergic inhibition, which reduces vascular resistance. Alcohol amplifies both arms of that effect.

Sex-Specific Pharmacokinetics Matter Here

Women metabolize alcohol more slowly than men, weight for weight, because of lower gastric alcohol dehydrogenase activity and a smaller volume of distribution for water-soluble compounds. That means even a single glass of wine may keep blood alcohol concentration elevated longer in a woman than in a man of equal body weight. Because the flibanserin-alcohol trial enrolled women specifically, the risk data you see in the label is women's data, not extrapolated from men. That is worth knowing.

Other CNS Depressants With Additive Risk

The additive hypotension and sedation risk extends beyond alcohol to any CNS depressant. This includes:

• Benzodiazepines (alprazolam, clonazepam, diazepam)
• Opioid analgesics
• Sedating antihistamines (diphenhydramine, hydroxyzine)
• Sleep medications, including zolpidem and eszopiclone
• Certain antidepressants with significant sedating properties, such as mirtazapine
• Gabapentinoids (gabapentin, pregabalin), which are frequently used in perimenopausal women for hot flashes and sleep

If you are perimenopausal and using gabapentin at bedtime for vasomotor symptoms, combining it with flibanserin at the same time carries overlapping CNS depression risk. Your clinician may adjust timing or avoid the combination entirely.

CYP3A4 and CYP2C19: The Metabolic Interactions That Change Everything

Flibanserin is metabolized primarily by CYP3A4 and secondarily by CYP2C19. This is where the longest and most clinically actionable list of interactions lives.

Strong CYP3A4 Inhibitors: Contraindicated

Strong CYP3A4 inhibitors can raise flibanserin plasma concentrations approximately 4.5-fold, dramatically increasing hypotension and syncope risk. The label contraindicates concurrent use. Drugs in this category include:

• Azole antifungals: fluconazole, itraconazole, ketoconazole, posaconazole
• Certain HIV antiretrovirals: ritonavir, lopinavir, atazanavir, indinavir, nelfinavir, saquinavir
• Clarithromycin and telithromycin (macrolide antibiotics)
• Conivaptan and nefazodone

If you need a short course of fluconazole for a vaginal yeast infection, which is a near-universal experience for women of reproductive age, you must stop flibanserin for at least 14 days before starting the fluconazole course and not restart until the fluconazole course ends. This is not optional. The exposure increase is large enough to produce clinically dangerous hypotension even at a standard 150 mg single dose of fluconazole.

Moderate CYP3A4 Inhibitors: Use With Caution

Moderate inhibitors raise flibanserin exposure meaningfully and require caution rather than an absolute contraindication. Common examples include:

• Grapefruit juice (consume no more than one small glass per day if you continue Addyi)
• Diltiazem and verapamil (used for blood pressure or heart-rate control)
• Erythromycin (common antibiotic)
• Oral contraceptives containing estrogen and progestins, which have weak-to-moderate CYP3A4 inhibitory properties
• Cimetidine (acid-reducing agent)

Hormonal contraception deserves specific attention here. A combined oral contraceptive pill may modestly raise flibanserin exposure through mild CYP3A4 inhibition, but the effect is not large enough to require stopping the pill. You should still use the most reliable contraception available, and your clinician should note that the combination may slightly increase flibanserin side effects like dizziness or nausea.

CYP3A4 Inducers: Reduced Efficacy

Strong CYP3A4 inducers decrease flibanserin plasma concentrations, potentially to sub-therapeutic levels. These include:

• Rifampin (tuberculosis treatment)
• Carbamazepine and phenytoin (anti-seizure drugs)
• St. John's Wort (widely used herbal supplement)

St. John's Wort is worth flagging specifically. Women commonly use it for mood and perimenopausal symptoms. It is a well-established CYP3A4 inducer and may reduce Addyi's already-modest efficacy. If you are taking both, discuss stopping the supplement before attributing a lack of Addyi response to the drug itself.

CYP2C19 Inhibitors

Fluconazole also inhibits CYP2C19. Omeprazole, esomeprazole (proton-pump inhibitors frequently used in women for gastroesophageal reflux), and fluvoxamine are CYP2C19 inhibitors. The CYP2C19 contribution to flibanserin metabolism is secondary, so these agents alone are less dangerous than CYP3A4 inhibitors, but the combination of CYP2C19 inhibition plus moderate CYP3A4 inhibition could be additive.

Addyi and Vaccines: A Clear Answer to a Common Question

Vaccines do not interact pharmacokinetically with flibanserin, and no pharmacodynamic interaction has been identified in the literature or in post-market surveillance. Here is the clinical reasoning.

Flibanserin is metabolized by hepatic CYP3A4 and CYP2C19 enzymes. Vaccines, whether inactivated (flu shot, Tdap, hepatitis B, HPV, COVID-19 mRNA, RSV), live-attenuated (MMR, varicella), or recombinant subunit (Shingrix), do not function as CYP enzyme substrates, inhibitors, or inducers. They are biologics that stimulate immune response, not small-molecule drugs competing for metabolic pathways.

Is There Any Theoretical Concern?

One theoretical question exists: severe systemic inflammatory responses to vaccines can transiently downregulate cytochrome P450 enzymes through inflammatory cytokine release, particularly IL-6. Studies in the context of therapeutic cytokine inhibitors show that IL-6 elevation can reduce CYP3A4 activity, and this has been studied in the context of monoclonal antibody therapies for rheumatoid arthritis. In practice, a routine flu shot or COVID-19 booster does not produce cytokine levels sufficient to meaningfully change CYP3A4 activity in a clinically relevant way. This effect has been documented for tocilizumab (an IL-6 receptor antagonist) affecting CYP3A4 substrates when tocilizumab is stopped, but it does not translate to routine vaccine immunization.

Practical Guidance: Can You Get Vaccinated While Taking Addyi?

Yes. You can receive any routinely recommended vaccine while taking flibanserin. There is no contraindication, no timing restriction, and no dose adjustment required. The CDC vaccination schedule for adults recommends annual influenza vaccination, an updated COVID-19 vaccine, Tdap if not previously received as an adult, Shingrix (two-dose series) starting at age 50, and HPV vaccination through age 26 (or shared decision-making through age 45). None of these require pausing Addyi.

If you develop a significant post-vaccine fever or systemic reaction, that is standard immune activation, not a drug interaction. Symptomatic management with acetaminophen is safe with flibanserin. NSAIDs (ibuprofen, naproxen) are also safe from an interaction standpoint, as they are not significant CYP3A4 inhibitors or inducers.

Age-Specific Vaccine Considerations for Women on Addyi

Because flibanserin is approved only for premenopausal women, most women taking it are between roughly 25 and 50 years old. In this age range, the vaccines most likely to be top of mind include:

• HPV vaccine (Gardasil 9) through age 45 under shared decision-making with your clinician
• Influenza vaccine annually
• COVID-19 updated booster per current CDC recommendations
• Hepatitis B series if not previously vaccinated, particularly important for women with multiple sexual partners or health-care exposure
• Tdap, especially if planning pregnancy

None of these interact with flibanserin.

Pregnancy, Lactation, and Contraception: What Every Woman Must Know

Flibanserin is contraindicated in pregnancy. This is not a soft caution. The FDA label states the drug should be discontinued immediately if pregnancy is confirmed.

Pregnancy Category and Human Data

Flibanserin was approved after the FDA retired the A/B/C/D/X letter-category system, so it carries a narrative Pregnancy section rather than a letter grade. Animal reproductive toxicity studies in rats showed embryo-fetal developmental effects at exposures exceeding the maximum recommended human dose. Human pregnancy data is essentially absent from the registration trials, because premenopausal women with HSDD who were trying to conceive were excluded.

Given the absence of reassuring human pregnancy data and the presence of concerning animal data, the label's position is straightforward: do not use during pregnancy.

Lactation

Human data on flibanserin transfer into breast milk does not exist. The drug and its metabolites are present in the milk of lactating rats. Because of the unknown risk to a breastfed infant and the non-essential nature of the indication (low sexual desire is not a life-threatening condition), the label recommends not breastfeeding while using flibanserin. This is a reasonable precaution given the data gap.

Contraception Requirement

Because flibanserin is contraindicated in pregnancy and is approved for premenopausal women (who may become pregnant), effective contraception is strongly advisable throughout treatment. The FDA ADDYI REMS program underscores this through the patient-provider agreement process. If you are using flibanserin and do not want to become pregnant, use reliable contraception consistently.

As noted above, combined hormonal contraception has a mild CYP3A4 inhibitory effect. This does not mean you should avoid it; it means your clinician should document the interaction in your chart and monitor for flibanserin side effects like dizziness or nausea.

Who This Drug May Be Right For, and Who Should Not Use It

Flibanserin fits a narrow clinical profile. The FDA approval specifies:

• Premenopausal women
• Acquired HSDD (desire was present at some point and has been lost, not lifelong low desire)
• Generalized HSDD (not situational, meaning the desire deficit is not limited to one partner or one setting)
• Distress about the low desire (the woman herself must find this bothersome)

Women Likely to Benefit

• Premenopausal women with acquired, generalized HSDD who have ruled out relationship factors, depression, thyroid dysfunction, and medication side effects (especially SSRIs, SNRIs, and hormonal contraceptives that suppress desire)
• Women who cannot or prefer not to use hormonal treatments for sexual dysfunction
• Women who have already tried psychotherapy-based approaches (mindfulness-based cognitive therapy, sex therapy) and want an adjunct

Women Who Should Not Use Addyi

• Postmenopausal or clearly perimenopausal women (off-label, limited data)
• Pregnant women or those trying to conceive
• Women who drink alcohol regularly and are unwilling or unable to abstain on dosing nights
• Women taking any strong CYP3A4 inhibitor, including fluconazole, ritonavir, or clarithromycin, who are not willing to complete appropriate washout periods
• Women with hepatic impairment, because flibanserin exposure increases substantially with reduced liver function, and the drug is contraindicated in this population
• Women whose low desire is clearly situational (partner-specific) or attributable to an undertreated mood disorder or SSRI side effect

PCOS Consideration

Women with PCOS have higher rates of depression, body image concerns, and hormonal contraceptive use, all of which can contribute to low sexual desire. Flibanserin may be an option for a premenopausal woman with PCOS and acquired HSDD, but clinicians should first address the hormonal and metabolic drivers of low desire before reaching for a CNS agent. There is no PCOS-specific efficacy data for flibanserin.

Managing Addyi Side Effects in Real Life

The most common adverse effects in the registration trials were dizziness, somnolence (sleepiness), nausea, fatigue, insomnia, and dry mouth. In the VIOLET trial, 13 percent of women discontinued due to adverse effects compared with 6 percent on placebo.

Taking the dose at bedtime rather than in the morning or evening was specifically chosen to minimize the window of active drug exposure during waking hours, reducing dizziness and somnolence when you are upright and mobile.

Practical steps that reduce side effects:

• Take the dose consistently at bedtime (not occasionally earlier in the evening)
• Avoid alcohol on dosing nights, period
• Start with adequate hydration; mild dehydration worsens hypotension risk
• Sit at the edge of the bed for a moment before standing at night if you need to use the bathroom

If dizziness or hypotension is significant, your clinician may consider whether any concurrent medications (antihypertensives, alpha blockers for bladder symptoms, or certain antidepressants) are contributing additively.

The Evidence Gap: What We Still Do Not Know

Women have historically been underrepresented in drug trials, and HSDD research is no exception in several respects. The VIOLET, BEGONIA, and SNOWDROP trials enrolled mostly white, partnered, heterosexual, premenopausal women in North America and Europe. The efficacy and safety data for:

• Women of color
• Women who identify as LGBTQ+
• Women in perimenopause or recent surgical menopause
• Women with comorbid autoimmune disease on immunomodulating drugs
• Women with a history of trauma-related sexual dysfunction

...are either absent or extremely limited. The satisfying sexual events-per-month endpoint used in the trials has also been criticized as insufficiently capturing the subjective experience of desire. When your clinician tells you the drug "works," they mean it shifted that one endpoint by roughly half an event per month on average across a population. Your individual response may be more, less, or nothing at all.

As our reviewer Dr. Rachel Goldberg notes: "The women I see who get the most from flibanserin are those who have already done the work of ruling out thyroid disease, optimizing their SSRI if they are on one, and addressing sleep. The drug does not substitute for that clinical evaluation. It layers onto it."